99 results on '"Goldberg, Jenna D."'
Search Results
2. Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
- Author
-
Girgis, Suzette, Wang Lin, Shun Xin, Pillarisetti, Kodandaram, Verona, Raluca, Vieyra, Diego, Casneuf, Tineke, Fink, Damien, Miao, Xin, Chen, Yang, Stephenson, Tara, Banerjee, Arnob, Hilder, Brandi W., Russell, Jeffery, Infante, Jeffrey, Elsayed, Yusri, Smit, Jennifer, and Goldberg, Jenna D.
- Published
- 2023
- Full Text
- View/download PDF
3. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study
- Author
-
Martin, Thomas, Lin, Yi, Agha, Mounzer, Cohen, Adam D, Htut, Myo, Stewart, A Keith, Hari, Parameswaran, Berdeja, Jesus G, Usmani, Saad Z, Yeh, Tzu-Min, Olyslager, Yunsi, Goldberg, Jenna D, Schecter, Jordan M, Madduri, Deepu, Jackson, Carolyn C, Deraedt, William, Gries, Katharine S, Fastenau, John M, Trudeau, Jeremiah J, Akram, Muhammad, Pacaud, Lida, Jakubowiak, Andrzej, and Jagannath, Sundar
- Abstract
CARTITUDE-1 is a phase 1b–2 study evaluating ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T cell therapy with two B-cell maturation antigen–targeting single-domain antibodies, in patients with relapsed or refractory multiple myeloma. Primary efficacy outcomes have previously been reported. Here, we report health-related quality of life (HRQOL) secondary outcomes evaluated using patient-reported outcomes.
- Published
- 2022
- Full Text
- View/download PDF
4. Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
- Author
-
Chari, Ajai, Touzeau, Cyrille, Schinke, Carolina, Minnema, Monique C., Berdeja, Jesus, Oriol, Albert, Van De Donk, Niels WCJ, Rodriguez Otero, Paula, Askari, Elham, Mateos, Maria-Victoria, Costa, Luciano J., Caers, Jo, Rasche, Leo, Krishnan, Amrita Y., Vishwamitra, Deeksha, Ma, Xuewen, Qin, Xiang, Gries, Katharine S., Campagna, Michela, Masterson, Tara, Hilder, Brandi, Tolbert, Jaszianne, Renaud, Thomas, Goldberg, Jenna D., Heuck, Christoph, San-Miguel, Jesús, and Moreau, Philippe
- Published
- 2022
- Full Text
- View/download PDF
5. Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
- Author
-
Chari, Ajai, Touzeau, Cyrille, Schinke, Carolina, Minnema, Monique C., Berdeja, Jesus, Oriol, Albert, Van De Donk, Niels WCJ, Rodriguez Otero, Paula, Askari, Elham, Mateos, Maria-Victoria, Costa, Luciano J., Caers, Jo, Rasche, Leo, Krishnan, Amrita Y., Vishwamitra, Deeksha, Ma, Xuewen, Qin, Xiang, Gries, Katharine S., Campagna, Michela, Masterson, Tara, Hilder, Brandi, Tolbert, Jaszianne, Renaud, Thomas, Goldberg, Jenna D., Heuck, Christoph, San-Miguel, Jesús, and Moreau, Philippe
- Published
- 2022
- Full Text
- View/download PDF
6. Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant
- Author
-
Sola, Maria, Bhatt, Valkal, Palazzo, Meighan, Cavalier, Kathleen E., Devlin, Sean M., Maloy, Molly, Barker, Juliet N., Castro-Malaspina, Hugo, Chung, David, Dahi, Parastoo B., Jakubowski, Ann A., Landau, Heather, Papadopoulos, Esperanza B., Perales, Miguel-Angel, Sauter, Craig, Tamari, Roni, Kernan, Nancy A., Giralt, Sergio, Young, James W., Goldberg, Jenna D., and Ponce, Doris M.
- Abstract
Hepatic sinusoidal obstruction syndrome (SOS) is a serious complication after allogeneic stem cell transplantation (allo-HCT). However, there is no uniform consensus on the optimal strategy for SOS prevention. Ursodeoxycholic acid is the most used regimen, even though its administration is challenging in recipients unable to tolerate oral medication. Defibrotide was recently studied in a phase 3 trial, but enrollment was stopped early due to futility. Low-dose unfractionated heparin (UFH) is an alternative strategy. However, its efficacy is reputed but unproven increased risk of bleeding has not been fully established. We evaluated 514 adult allo-HCT recipients who received SOS prophylaxis with low-dose UFH. Bleeding complications occurred in 12 patients 2.3% of patients of which only 2 (0.4%) had significant grade 3 bleeding. Only 14 patients were diagnosed with hepatic SOS. Univariate analysis showed that day 100 SOS was higher in recipients of unmodified grafts when compared to CD34+ selected ex vivo T-cell depleted grafts (p≤ 0.001), and patients with hepatitis B and/or C exposure pre-HCT (p= 0.028). Overall, UFH was well tolerated and associated with a low incidence of subsequent hepatic SOS. Low-dose UFH prophylaxis can be considered in select patients who cannot tolerate oral ursodiol.
- Published
- 2022
- Full Text
- View/download PDF
7. Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
- Author
-
Touzeau, Cyrille, Chari, Ajai, Schinke, Carolina, Minnema, Monique C., Berdeja, Jesus, Oriol, Albert, Van De Donk, Niels WCJ, Rodriguez Otero, Paula, Askari, Elham, Mateos, Maria-Victoria, Costa, Luciano J., Caers, Jo, Rasche, Leo, Krishnan, Amrita Y., Vishwamitra, Deeksha, Ma, Xuewen, Qin, Xiang, Gries, Katharine S., Kato, Kelly, Campagna, Michela, Masterson, Tara, Hilder, Brandi, Tolbert, Jaszianne, Renaud, Thomas, Goldberg, Jenna D., Heuck, Chris, Moreau, Philippe, and San-Miguel, Jesús
- Published
- 2022
- Full Text
- View/download PDF
8. Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
- Author
-
Touzeau, Cyrille, Chari, Ajai, Schinke, Carolina, Minnema, Monique C., Berdeja, Jesus, Oriol, Albert, Van De Donk, Niels WCJ, Rodriguez Otero, Paula, Askari, Elham, Mateos, Maria-Victoria, Costa, Luciano J., Caers, Jo, Rasche, Leo, Krishnan, Amrita Y., Vishwamitra, Deeksha, Ma, Xuewen, Qin, Xiang, Gries, Katharine S., Kato, Kelly, Campagna, Michela, Masterson, Tara, Hilder, Brandi, Tolbert, Jaszianne, Renaud, Thomas, Goldberg, Jenna D., Heuck, Chris, Moreau, Philippe, and San-Miguel, Jesús
- Published
- 2022
- Full Text
- View/download PDF
9. Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
- Author
-
Cortes-Selva, Diana, Casneuf, Tineke, Vishwamitra, Deeksha, Stein, Sarah, Perova, Tatiana, Skerget, Sheri, Ramos, Elena, van Steenbergen, Laure, De Maeyer, Dries, Boominathan, Rengasamy, Lau, Onsay, Davis, Cuc, Banerjee, Arnob, Stephenson, Tara, Uhlar, Clarissa M., Kobos, Rachel, Goldberg, Jenna D., Pei, Lixia, Trancucci, Danielle, Girgis, Suzette, Wang Lin, Shun Xin, Wu, Liviawati S., Moreau, Philippe, Usmani, Saad, Bahlis, Nizar Jacques, Van De Donk, Niels WCJ, and Verona, Raluca
- Published
- 2022
- Full Text
- View/download PDF
10. Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
- Author
-
Searle, Emma, Quach, Hang, Wong, Sandy W., Costa, Luciano J., Hulin, Cyrille, Janowski, Wojciech, Berdeja, Jesus, Anguille, Sébastien, Matous, Jeffrey V., Touzeau, Cyrille, Michallet, Anne-Sophie, Husnik, Marla, Vishwamitra, Deeksha, Niu, Zhuolu, Larsen, Julie, Chen, Lingling, Goldberg, Jenna D., Popat, Rakesh, and Spencer, Andrew
- Published
- 2022
- Full Text
- View/download PDF
11. Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
- Author
-
Cortes-Selva, Diana, Casneuf, Tineke, Vishwamitra, Deeksha, Stein, Sarah, Perova, Tatiana, Skerget, Sheri, Ramos, Elena, van Steenbergen, Laure, De Maeyer, Dries, Boominathan, Rengasamy, Lau, Onsay, Davis, Cuc, Banerjee, Arnob, Stephenson, Tara, Uhlar, Clarissa M., Kobos, Rachel, Goldberg, Jenna D., Pei, Lixia, Trancucci, Danielle, Girgis, Suzette, Wang Lin, Shun Xin, Wu, Liviawati S., Moreau, Philippe, Usmani, Saad, Bahlis, Nizar Jacques, Van De Donk, Niels WCJ, and Verona, Raluca
- Published
- 2022
- Full Text
- View/download PDF
12. Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
- Author
-
Searle, Emma, Quach, Hang, Wong, Sandy W., Costa, Luciano J., Hulin, Cyrille, Janowski, Wojciech, Berdeja, Jesus, Anguille, Sébastien, Matous, Jeffrey V., Touzeau, Cyrille, Michallet, Anne-Sophie, Husnik, Marla, Vishwamitra, Deeksha, Niu, Zhuolu, Larsen, Julie, Chen, Lingling, Goldberg, Jenna D., Popat, Rakesh, and Spencer, Andrew
- Published
- 2022
- Full Text
- View/download PDF
13. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
- Author
-
Usmani, Saad Z, Garfall, Alfred L, van de Donk, Niels W C J, Nahi, Hareth, San-Miguel, Jesus F, Oriol, Albert, Rosinol, Laura, Chari, Ajai, Bhutani, Manisha, Karlin, Lionel, Benboubker, Lotfi, Pei, Lixia, Verona, Raluca, Girgis, Suzette, Stephenson, Tara, Elsayed, Yusri, Infante, Jeffrey, Goldberg, Jenna D, Banerjee, Arnob, Mateos, María-Victoria, and Krishnan, Amrita
- Abstract
There is a need for novel therapies for relapsed or refractory multiple myeloma, and B-cell maturation antigen (BCMA) is a validated target. Teclistamab is a bispecific antibody that binds BCMA and CD3 to redirect T cells to multiple myeloma cells. The aim of the MajesTEC-1 study was to evaluate the safety, tolerability, and preliminary efficacy of teclistamab in patients with relapsed or refractory multiple myeloma.
- Published
- 2021
- Full Text
- View/download PDF
14. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- Author
-
Berdeja, Jesus G, Madduri, Deepu, Usmani, Saad Z, Jakubowiak, Andrzej, Agha, Mounzer, Cohen, Adam D, Stewart, A Keith, Hari, Parameswaran, Htut, Myo, Lesokhin, Alexander, Deol, Abhinav, Munshi, Nikhil C, O'Donnell, Elizabeth, Avigan, David, Singh, Indrajeet, Zudaire, Enrique, Yeh, Tzu-Min, Allred, Alicia J, Olyslager, Yunsi, Banerjee, Arnob, Jackson, Carolyn C, Goldberg, Jenna D, Schecter, Jordan M, Deraedt, William, Zhuang, Sen Hong, Infante, Jeffrey, Geng, Dong, Wu, Xiaoling, Carrasco-Alfonso, Marlene J, Akram, Muhammad, Hossain, Farah, Rizvi, Syed, Fan, Frank, Lin, Yi, Martin, Thomas, and Jagannath, Sundar
- Abstract
CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients with relapsed or refractory multiple myeloma with poor prognosis.
- Published
- 2021
- Full Text
- View/download PDF
15. CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma
- Author
-
Madduri, Deepu, Berdeja, Jesus G., Usmani, Saad Z., Jakubowiak, Andrzej, Agha, Mounzer, Cohen, Adam D., Stewart, A. Keith, Hari, Parameswaran, Htut, Myo, O'Donnell, Elizabeth, Munshi, Nikhil C., Avigan, David E., Deol, Abhinav, Lesokhin, Alexander M., Singh, Indrajeet, Zudaire, Enrique, Yeh, Tzu-Min, Allred, Alicia J., Olyslager, Yunsi, Banerjee, Arnob, Goldberg, Jenna D., Schecter, Jordan M., Jackson, Carolyn C., Deraedt, William, Zhuang, Sen Hong, Infante, Jeffrey R., Geng, Dong, Wu, Xiaoling, Carrasco, Marlene J., Akram, Muhammad, Hossain, Farah, Rizvi, Syed, Fan, Frank, Jagannath, Sundar, Lin, Yi, and Martin, Thomas
- Abstract
Madduri: Celgene: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Foundation Medicine: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Legend: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Speaking Engagement, Speakers Bureau; Kinevant: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Speaking Engagement, Speakers Bureau; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Speaking Engagement, Speakers Bureau. Berdeja:Teva: Research Funding; Bluebird: Research Funding; Bioclinica: Consultancy; Celgene: Consultancy, Research Funding; EMD Sorono: Research Funding; Kite Pharma: Consultancy; Prothena: Consultancy; Cellularity: Research Funding; Karyopharm: Consultancy; Servier: Consultancy; Legend: Consultancy; Poseida: Research Funding; Lilly: Research Funding; Acetylon: Research Funding; CURIS: Research Funding; Janssen: Consultancy, Research Funding; Genentech, Inc.: Research Funding; Glenmark: Research Funding; Takeda: Consultancy, Research Funding; BMS: Consultancy, Research Funding; Constellation: Research Funding; CRISPR Therapeutics: Consultancy, Research Funding; Vivolux: Research Funding; Abbvie: Research Funding; Amgen: Consultancy, Research Funding; Kesios: Research Funding; Novartis: Research Funding. Usmani:Celgene: Other; BMS, Celgene: Consultancy, Honoraria, Other: Speaking Fees, Research Funding; GSK: Consultancy, Research Funding; Pharmacyclics: Research Funding; Merck: Consultancy, Research Funding; Abbvie: Consultancy; Sanofi: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Other: Speaking Fees, Research Funding; Janssen: Consultancy, Honoraria, Other: Speaking Fees, Research Funding; SkylineDX: Consultancy, Research Funding; Seattle Genetics: Consultancy, Research Funding; Incyte: Research Funding; Array Biopharma: Research Funding; Amgen: Consultancy, Honoraria, Other: Speaking Fees, Research Funding. Jakubowiak:Adaptive, Juno: Consultancy, Honoraria; AbbVie, Amgen, BMS/Celgene, GSK, Janssen, Karyopharm: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Cohen:Celgene: Membership on an entity's Board of Directors or advisory committees; Takeda,: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Kite Pharma: Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Genentech/Roche: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Other: Patents/Intellectual property licensed, Research Funding. Stewart:Janssen, BMS, Sanofi-Aventis, GSK: Honoraria; Tempus, Inc., Genomics England LLC: Membership on an entity's Board of Directors or advisory committees. Hari:Amgen: Consultancy; BMS: Consultancy; GSK: Consultancy; Janssen: Consultancy; Takeda: Consultancy; Incyte Corporation: Consultancy. Htut:City of Hope Medical Center: Current Employment. Munshi:OncoPep: Consultancy, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties; BMS: Consultancy; Janssen: Consultancy; Adaptive: Consultancy; Legend: Consultancy; Amgen: Consultancy; Karyopharm: Consultancy; Takeda: Consultancy; AbbVie: Consultancy; C4: Current equity holder in private company. Deol:Novartis: Consultancy; Kite, a Gilead Company: Consultancy. Lesokhin:BMS: Consultancy, Honoraria, Research Funding; Genentech: Research Funding; Janssen: Research Funding; Juno: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Serametrix Inc.: Patents & Royalties; GenMab: Consultancy, Honoraria. Singh:Janssen: Current Employment. Zudaire:Janssen: Current Employment. Yeh:Janssen: Current Employment. Allred:Janssen: Current Employment. Olyslager:Janssen: Current Employment. Banerjee:Janssen: Current Employment. Goldberg:Johnson & Johnson: Current Employment, Current equity holder in publicly-traded company. Schecter:Janssen: Current Employment. Jackson:Janssen: Current Employment; Memorial Sloan Kettering Cancer Center: Consultancy. Deraedt:Janssen: Current Employment, Current equity holder in publicly-traded company. Zhuang:Janssen: Current Employment. Infante:Janssen: Current Employment. Geng:Legend Biotech USA Inc.: Current Employment. Wu:Legend Biotech USA Inc.: Current Employment. Carrasco:Legend Biotech USA Inc.: Current Employment. Akram:Legend Biotech USA Inc.: Current Employment. Hossain:Legend Biotech USA Inc.: Current Employment. Rizvi:Legend Biotech USA Inc.: Current Employment. Fan:Legend Biotech USA Inc.: Current Employment. Jagannath:BMS, Janssen, Karyopharm, Legend Biotech, Sanofi, Takeda: Consultancy. Lin:Kite, a Gilead Company: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Merck: Research Funding; Legend BioTech: Consultancy; Juno: Consultancy; Bluebird Bio: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Novartis: Consultancy; Vineti: Consultancy; Takeda: Research Funding; Gamida Cells: Consultancy; Sorrento: Consultancy, Membership on an entity's Board of Directors or advisory committees. Martin:AMGEN: Research Funding; Seattle Genetics: Research Funding; Janssen: Research Funding; GSK: Consultancy; Sanofi: Research Funding.
- Published
- 2020
- Full Text
- View/download PDF
16. CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma
- Author
-
Madduri, Deepu, Berdeja, Jesus G., Usmani, Saad Z., Jakubowiak, Andrzej, Agha, Mounzer, Cohen, Adam D., Stewart, A. Keith, Hari, Parameswaran, Htut, Myo, O'Donnell, Elizabeth, Munshi, Nikhil C., Avigan, David E., Deol, Abhinav, Lesokhin, Alexander M., Singh, Indrajeet, Zudaire, Enrique, Yeh, Tzu-Min, Allred, Alicia J., Olyslager, Yunsi, Banerjee, Arnob, Goldberg, Jenna D., Schecter, Jordan M., Jackson, Carolyn C., Deraedt, William, Zhuang, Sen Hong, Infante, Jeffrey R., Geng, Dong, Wu, Xiaoling, Carrasco, Marlene J., Akram, Muhammad, Hossain, Farah, Rizvi, Syed, Fan, Frank, Jagannath, Sundar, Lin, Yi, and Martin, Thomas
- Abstract
Background:Ciltacabtagene autoleucel (cilta-cel; JNJ-68284528; LCAR-B38M CAR-T cells) is a chimeric antigen receptor T (CAR-T) cell therapy with 2 B-cell maturation antigen-targeting single-domain antibodies designed to confer avidity. In the phase 1 LEGEND-2 study in China, LCAR-B38M yielded deep, durable responses with a manageable safety profile in patients (pts) with relapsed/refractory multiple myeloma (R/R MM). The phase 1b/2 CARTITUDE-1 study (NCT03548207) is further evaluating cilta-cel in this pt population in the US. We present updated data from the phase 1b portion along with initial phase 2 data.
- Published
- 2020
- Full Text
- View/download PDF
17. Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
- Author
-
Cohen, Adam D., Hari, Parameswaran, Htut, Myo, Berdeja, Jesus G., Madduri, Deepu, Usmani, Saad Z., Allred, Alicia J., Olyslager, Yunsi, Banerjee, Arnob, Goldberg, Jenna D., Schecter, Jordan M., Jackson, Carolyn C., Gries, Katharine S., Fastenau, John, Deraedt, William, Carrasco, Marlene J., Akram, Muhammad, Hossain, Farah, Crawford, Sigrid, Morrison, Ross, Doward, Lynda, Jakubowiak, Andrzej, and Jagannath, Sundar
- Abstract
Cohen: Novartis: Other: Patents/Intellectual property licensed, Research Funding; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees; Takeda,: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Kite Pharma: Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Genentech/Roche: Membership on an entity's Board of Directors or advisory committees. Hari:GSK: Consultancy; Amgen: Consultancy; Incyte Corporation: Consultancy; Janssen: Consultancy; BMS: Consultancy; Takeda: Consultancy. Htut:City of Hope Medical Center: Current Employment. Berdeja:CURIS: Research Funding; Constellation: Research Funding; Janssen: Consultancy, Research Funding; Vivolux: Research Funding; Abbvie: Research Funding; Amgen: Consultancy, Research Funding; Poseida: Research Funding; Kesios: Research Funding; EMD Sorono: Research Funding; Glenmark: Research Funding; Novartis: Research Funding; Legend: Consultancy; Kite Pharma: Consultancy; Acetylon: Research Funding; Prothena: Consultancy; Celgene: Consultancy, Research Funding; Genentech, Inc.: Research Funding; Teva: Research Funding; Servier: Consultancy; Takeda: Consultancy, Research Funding; Cellularity: Research Funding; Lilly: Research Funding; Bluebird: Research Funding; CRISPR Therapeutics: Consultancy, Research Funding; BMS: Consultancy, Research Funding; Bioclinica: Consultancy; Karyopharm: Consultancy. Madduri:Janssen: Consultancy, Honoraria; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Speaking Engagement, Speakers Bureau; Legend: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Speaking Engagement, Speakers Bureau; Takeda: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Foundation Medicine: Consultancy, Honoraria; Kinevant: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Speaking Engagement, Speakers Bureau; AbbVie: Consultancy, Honoraria. Usmani:Celgene: Other; Amgen: Consultancy, Honoraria, Other: Speaking Fees, Research Funding; BMS, Celgene: Consultancy, Honoraria, Other: Speaking Fees, Research Funding; Abbvie: Consultancy; Sanofi: Consultancy, Honoraria, Research Funding; GSK: Consultancy, Research Funding; Pharmacyclics: Research Funding; Incyte: Research Funding; Janssen: Consultancy, Honoraria, Other: Speaking Fees, Research Funding; Merck: Consultancy, Research Funding; SkylineDX: Consultancy, Research Funding; Seattle Genetics: Consultancy, Research Funding; Takeda: Consultancy, Honoraria, Other: Speaking Fees, Research Funding; Array Biopharma: Research Funding. Allred:Janssen: Current Employment. Olyslager:Janssen: Current Employment. Banerjee:Janssen: Current Employment. Goldberg:Johnson & Johnson: Current Employment, Current equity holder in publicly-traded company. Schecter:Janssen: Current Employment. Jackson:Memorial Sloan Kettering Cancer Center: Consultancy; Janssen: Current Employment. Gries:Janssen: Current Employment, Current equity holder in publicly-traded company. Fastenau:Janssen: Current Employment, Current equity holder in publicly-traded company. Deraedt:Janssen: Current Employment, Current equity holder in publicly-traded company. Carrasco:Legend Biotech USA Inc.: Current Employment. Akram:Legend Biotech USA Inc.: Current Employment. Hossain:Legend Biotech USA Inc.: Current Employment. Crawford:RTI Health Solutions: Current Employment. Morrison:RTI Health Solutions: Current Employment. Doward:RTI Health Solutions: Current Employment. Jakubowiak:AbbVie, Amgen, BMS/Celgene, GSK, Janssen, Karyopharm: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive, Juno: Consultancy, Honoraria. Jagannath:BMS, Janssen, Karyopharm, Legend Biotech, Sanofi, Takeda: Consultancy.
- Published
- 2020
- Full Text
- View/download PDF
18. Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
- Author
-
Cohen, Adam D., Hari, Parameswaran, Htut, Myo, Berdeja, Jesus G., Madduri, Deepu, Usmani, Saad Z., Allred, Alicia J., Olyslager, Yunsi, Banerjee, Arnob, Goldberg, Jenna D., Schecter, Jordan M., Jackson, Carolyn C., Gries, Katharine S., Fastenau, John, Deraedt, William, Carrasco, Marlene J., Akram, Muhammad, Hossain, Farah, Crawford, Sigrid, Morrison, Ross, Doward, Lynda, Jakubowiak, Andrzej, and Jagannath, Sundar
- Abstract
Background:Patients (pts) with multiple myeloma (MM) experience health-related quality of life (HRQoL) decrement due to symptoms such as fatigue, pain, and insomnia. Pt perspectives of their disease and treatment expectations can help inform clinical decision-making. The phase 1b/2 CARTITUDE-1 study (NCT03548207) is evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528; LCAR-B38M CAR-T cells), a chimeric antigen receptor T (CAR-T) cell therapy with 2 B-cell maturation antigen-targeting single-domain antibodies, in pts with relapsed/refractory (R/R) MM. An exploratory objective is to describe pretreatment goals and expectations and post-treatment experience of cilta-cel using qualitative interviews.
- Published
- 2020
- Full Text
- View/download PDF
19. Drug Interaction Potential As a Result of Cytokine Release Syndrome Using a Physiologically Based Pharmacokinetic Model: Case Study of Teclistamab
- Author
-
Willemin, Marie-Emilie, Wang Lin, Shun Xin, De Zwart, Loeckie, Wu, Liviawati S., Miao, Xin, Verona, Raluca, Banerjee, Arnob, Liu, Baolian, Kobos, Rachel, Qi, Ming, Ouellet, Daniele, Goldberg, Jenna D., and Girgis, Suzette
- Published
- 2022
- Full Text
- View/download PDF
20. Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma
- Author
-
Miao, Xin, Wu, Liviawati S., Wang Lin, Shun Xin, Xu, Yan, Chen, Yang, Iwaki, Yuki, Kobos, Rachel, Stephenson, Tara, Kemmerer, Kristy, Uhlar, Clarissa M., Banerjee, Arnob, Goldberg, Jenna D., Trancucci, Danielle, Verona, Raluca, Pei, Lixia, Su, Yaming, Ouellet, Daniele, Garfall, Alfred L., Krishnan, Amrita Y., Usmani, Saad, Girgis, Suzette, and Zhou, Honghui
- Published
- 2022
- Full Text
- View/download PDF
21. Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma
- Author
-
Miao, Xin, Wu, Liviawati S., Wang Lin, Shun Xin, Xu, Yan, Chen, Yang, Iwaki, Yuki, Kobos, Rachel, Stephenson, Tara, Kemmerer, Kristy, Uhlar, Clarissa M., Banerjee, Arnob, Goldberg, Jenna D., Trancucci, Danielle, Verona, Raluca, Pei, Lixia, Su, Yaming, Ouellet, Daniele, Garfall, Alfred L., Krishnan, Amrita Y., Usmani, Saad, Girgis, Suzette, and Zhou, Honghui
- Published
- 2022
- Full Text
- View/download PDF
22. Drug Interaction Potential As a Result of Cytokine Release Syndrome Using a Physiologically Based Pharmacokinetic Model: Case Study of Teclistamab
- Author
-
Willemin, Marie-Emilie, Wang Lin, Shun Xin, De Zwart, Loeckie, Wu, Liviawati S., Miao, Xin, Verona, Raluca, Banerjee, Arnob, Liu, Baolian, Kobos, Rachel, Qi, Ming, Ouellet, Daniele, Goldberg, Jenna D., and Girgis, Suzette
- Published
- 2022
- Full Text
- View/download PDF
23. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
- Author
-
Dreyling, Martin, Jurczak, Wojciech, Jerkeman, Mats, Silva, Rodrigo Santucci, Rusconi, Chiara, Trneny, Marek, Offner, Fritz, Caballero, Dolores, Joao, Cristina, Witzens-Harig, Mathias, Hess, Georg, Bence-Bruckler, Isabelle, Cho, Seok-Goo, Bothos, John, Goldberg, Jenna D, Enny, Christopher, Traina, Shana, Balasubramanian, Sriram, Bandyopadhyay, Nibedita, Sun, Steven, Vermeulen, Jessica, Rizo, Aleksandra, and Rule, Simon
- Abstract
Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the efficacy and safety of ibrutinib versus temsirolimus in relapsed or refractory mantle-cell lymphoma.
- Published
- 2016
- Full Text
- View/download PDF
24. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation
- Author
-
Ponce, Doris M., Hilden, Patrick, Mumaw, Christen, Devlin, Sean M., Lubin, Marissa, Giralt, Sergio, Goldberg, Jenna D., Hanash, Alan, Hsu, Katharine, Jenq, Robert, Perales, Miguel-Angel, Sauter, Craig, van den Brink, MarcelR. M., Young, James W., Brentjens, Renier, Kernan, Nancy A., Prockop, Susan E., O’Reilly, Richard J., Scaradavou, Andromachi, Paczesny, Sophie, and Barker, Juliet N.
- Abstract
While cord blood transplantation (CBT) is an effective therapy for hematologic malignancies, acute graft-versus-host disease (aGVHD) is a leading cause of transplant-related mortality (TRM). We investigated if biomarkers could predict aGVHD and TRM after day 28 in CBT recipients. Day 28 samples from 113 CBT patients were analyzed. Suppressor of tumorigenicity 2 (ST2) was the only biomarker associated with grades II-IV and III-IV aGVHD and TRM. Day 180 grade III-IV aGVHD in patients with high ST2 levels was 30% (95% confidence interval [CI], 18-43) vs 13% (95% CI, 5-23) in patients with low levels (P= .024). The adverse effect of elevated ST2 was independent of HLA match. Moreover, high day 28 ST2 levels were associated with increased TRM with day 180 estimates of 23% (95% CI, 13-35) vs 5% (95% CI, 1-13) if levels were low (P= .001). GVHD was the most common cause of death in high ST2 patients. High concentrations of tumor necrosis factor receptor-1, interleukin-8, and regenerating islet-derived protein 3-α were also associated with TRM. Our results are consistent with those of adult donor allografts and warrant further prospective evaluation to facilitate future therapeutic intervention to ameliorate severe aGVHD and further improve survival after CBT.
- Published
- 2015
- Full Text
- View/download PDF
25. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation
- Author
-
Ponce, Doris M., Hilden, Patrick, Mumaw, Christen, Devlin, Sean M., Lubin, Marissa, Giralt, Sergio, Goldberg, Jenna D., Hanash, Alan, Hsu, Katharine, Jenq, Robert, Perales, Miguel-Angel, Sauter, Craig, van den Brink, Marcel R. M., Young, James W., Brentjens, Renier, Kernan, Nancy A., Prockop, Susan E., O’Reilly, Richard J., Scaradavou, Andromachi, Paczesny, Sophie, and Barker, Juliet N.
- Abstract
While cord blood transplantation (CBT) is an effective therapy for hematologic malignancies, acute graft-versus-host disease (aGVHD) is a leading cause of transplant-related mortality (TRM). We investigated if biomarkers could predict aGVHD and TRM after day 28 in CBT recipients. Day 28 samples from 113 CBT patients were analyzed. Suppressor of tumorigenicity 2 (ST2) was the only biomarker associated with grades II-IV and III-IV aGVHD and TRM. Day 180 grade III-IV aGVHD in patients with high ST2 levels was 30% (95% confidence interval [CI], 18-43) vs 13% (95% CI, 5-23) in patients with low levels (P = .024). The adverse effect of elevated ST2 was independent of HLA match. Moreover, high day 28 ST2 levels were associated with increased TRM with day 180 estimates of 23% (95% CI, 13-35) vs 5% (95% CI, 1-13) if levels were low (P = .001). GVHD was the most common cause of death in high ST2 patients. High concentrations of tumor necrosis factor receptor-1, interleukin-8, and regenerating islet-derived protein 3-α were also associated with TRM. Our results are consistent with those of adult donor allografts and warrant further prospective evaluation to facilitate future therapeutic intervention to ameliorate severe aGVHD and further improve survival after CBT.
- Published
- 2015
- Full Text
- View/download PDF
26. Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
- Author
-
Cohen, Adam D., Hari, Parameswaran, Htut, Myo, Berdeja, Jesus G., Madduri, Deepu, Usmani, Saad Z., Allred, Alicia J., Olyslager, Yunsi, Banerjee, Arnob, Goldberg, Jenna D., Schecter, Jordan M., Jackson, Carolyn C., Gries, Katharine S., Fastenau, John, Deraedt, William, Carrasco-Alfonso, Marlene J., Akram, Muhammad, Hossain, Farah, Crawford, Rebecca, Morrison, Ross, Doward, Lynda, Jakubowiak, Andrzej, and Jagannath, Sundar
- Published
- 2021
- Full Text
- View/download PDF
27. Health-Related Quality of Life in the CARTITUDE-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma
- Author
-
Martin, Thomas, Lin, Yi, Agha, Mounzer, Cohen, Adam D., Htut, Myo, Stewart, A. Keith, Hari, Parameswaran, Berdeja, Jesus G., Madduri, Deepu, Usmani, Saad Z., Yeh, Tzu-Min, Allred, Alicia J., Olyslager, Yunsi, Banerjee, Arnob, Goldberg, Jenna D., Schecter, Jordan M., Jackson, Carolyn C., Deraedt, William, Gries, Katharine S., Fastenau, John, Wu, Xiaoling, Carrasco-Alfonso, Marlene, Akram, Muhammad, Hossain, Farah, Jakubowiak, Andrzej, and Jagannath, Sundar
- Published
- 2021
- Full Text
- View/download PDF
28. Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study
- Author
-
Lin, Yi, Martin, Thomas, Cohen, Adam D., Jakubowiak, Andrzej, Jasielec, Jagoda, Usmani, Saad Z., Madduri, Deepu, Agha, Mounzer, Stewart, A. Keith, Singh, Indrajeet, Zudaire, Enrique, Yeh, Tzu-Min, Allred, Alicia J., Olyslager, Yunsi, Banerjee, Arnob, Goldberg, Jenna D., Schecter, Jordan M., Jackson, Carolyn C., Deraedt, William, Geng, Dong, Wu, Xiaoling, Carrasco-Alfonso, Marlene, Akram, Muhammad, Hossain, Farah, Wang, Vickie, Berdeja, Jesus G., and Jagannath, Sundar
- Published
- 2021
- Full Text
- View/download PDF
29. Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study
- Author
-
Lin, Yi, Martin, Thomas, Cohen, Adam D., Jakubowiak, Andrzej, Jasielec, Jagoda, Usmani, Saad Z., Madduri, Deepu, Agha, Mounzer, Stewart, A. Keith, Singh, Indrajeet, Zudaire, Enrique, Yeh, Tzu-Min, Allred, Alicia J., Olyslager, Yunsi, Banerjee, Arnob, Goldberg, Jenna D., Schecter, Jordan M., Jackson, Carolyn C., Deraedt, William, Geng, Dong, Wu, Xiaoling, Carrasco, Marlene J., Akram, Muhammad, Hossain, Farah, Wang, Vickie, Berdeja, Jesus G., and Jagannath, Sundar
- Abstract
Background:The phase 1b/2 CARTITUDE-1 study (NCT03548207) is evaluating ciltacabtagene autoleucel (cilta-cel; JNJ-68284528; LCAR-B38M CAR-T cells), a chimeric antigen receptor T (CAR-T) cell therapy with 2 B-cell maturation antigen-targeting single-domain antibodies, in patients with relapsed/refractory (R/R) multiple myeloma (MM). Cytokine release syndrome (CRS), a known side effect of CAR-T therapy, can be mild to life-threatening and requires careful monitoring and management. Here, we analyzed CRS and cytokine profiles in CARTITUDE-1.
- Published
- 2020
- Full Text
- View/download PDF
30. Health-Related Quality of Life in the Cartitude-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma
- Author
-
Martin, Thomas, Lin, Yi, Agha, Mounzer, Cohen, Adam D., Htut, Myo, Stewart, A. Keith, Hari, Parameswaran, Berdeja, Jesus G., Madduri, Deepu, Usmani, Saad Z., Yeh, Tzu-Min, Allred, Alicia J., Olyslager, Yunsi, Banerjee, Arnob, Goldberg, Jenna D., Schecter, Jordan M., Jackson, Carolyn C., Deraedt, William, Gries, Katharine S., Fastenau, John, Wu, Xiaoling, Carrasco, Marlene J., Akram, Muhammad, Hossain, Farah, Jakubowiak, Andrzej, and Jagannath, Sundar
- Abstract
Background:Multiple myeloma (MM) negatively affects health-related quality of life (HRQoL), and with each relapse, patients with MM experience further declines in HRQoL. Patient-reported HRQoL is therefore an important treatment outcome, in addition to clinical response to therapy. CARTITUDE-1 (NCT03548207) is a phase 1b/2 study evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528; LCAR-B38M CAR-T cells), a chimeric antigen receptor T (CAR-T) cell therapy with 2 B-cell maturation antigen-targeting single-domain antibodies, in patients with relapsed/refractory (R/R) MM. We evaluated symptoms, functioning, and overall HRQoL through patient-reported outcome measures, which is a secondary objective of CARTITUDE-1.
- Published
- 2020
- Full Text
- View/download PDF
31. Health-Related Quality of Life in the Cartitude-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma
- Author
-
Martin, Thomas, Lin, Yi, Agha, Mounzer, Cohen, Adam D., Htut, Myo, Stewart, A. Keith, Hari, Parameswaran, Berdeja, Jesus G., Madduri, Deepu, Usmani, Saad Z., Yeh, Tzu-Min, Allred, Alicia J., Olyslager, Yunsi, Banerjee, Arnob, Goldberg, Jenna D., Schecter, Jordan M., Jackson, Carolyn C., Deraedt, William, Gries, Katharine S., Fastenau, John, Wu, Xiaoling, Carrasco, Marlene J., Akram, Muhammad, Hossain, Farah, Jakubowiak, Andrzej, and Jagannath, Sundar
- Abstract
Martin: Janssen: Research Funding; Sanofi: Research Funding; AMGEN: Research Funding; Seattle Genetics: Research Funding; GSK: Consultancy. Lin:Vineti: Consultancy; Janssen: Consultancy, Research Funding; Kite, a Gilead Company: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Novartis: Consultancy; Legend BioTech: Consultancy; Bluebird Bio: Consultancy, Research Funding; Juno: Consultancy; Merck: Research Funding; Takeda: Research Funding; Gamida Cells: Consultancy; Sorrento: Consultancy, Membership on an entity's Board of Directors or advisory committees. Cohen:Kite Pharma: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees; Takeda,: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Novartis: Other: Patents/Intellectual property licensed, Research Funding; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Genentech/Roche: Membership on an entity's Board of Directors or advisory committees. Htut:City of Hope Medical Center: Current Employment. Stewart:Janssen, BMS, Sanofi-Aventis, GSK: Honoraria; Tempus, Inc., Genomics England LLC: Membership on an entity's Board of Directors or advisory committees. Hari:GSK: Consultancy; BMS: Consultancy; Takeda: Consultancy; Amgen: Consultancy; Incyte Corporation: Consultancy; Janssen: Consultancy. Berdeja:Teva: Research Funding; Cellularity: Research Funding; Kesios: Research Funding; BMS: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; CURIS: Research Funding; EMD Sorono: Research Funding; Genentech, Inc.: Research Funding; Karyopharm: Consultancy; Poseida: Research Funding; Novartis: Research Funding; Lilly: Research Funding; Amgen: Consultancy, Research Funding; Acetylon: Research Funding; Glenmark: Research Funding; Janssen: Consultancy, Research Funding; Vivolux: Research Funding; Takeda: Consultancy, Research Funding; Servier: Consultancy; CRISPR Therapeutics: Consultancy, Research Funding; Constellation: Research Funding; Bluebird: Research Funding; Abbvie: Research Funding; Prothena: Consultancy; Bioclinica: Consultancy; Kite Pharma: Consultancy; Legend: Consultancy. Madduri:Foundation Medicine: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Speaking Engagement, Speakers Bureau; AbbVie: Consultancy, Honoraria; Legend: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Speaking Engagement, Speakers Bureau; Kinevant: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Speaking Engagement, Speakers Bureau; Celgene: Consultancy, Honoraria. Usmani:Takeda: Consultancy, Honoraria, Other: Speaking Fees, Research Funding; SkylineDX: Consultancy, Research Funding; Seattle Genetics: Consultancy, Research Funding; Merck: Consultancy, Research Funding; Incyte: Research Funding; Pharmacyclics: Research Funding; Janssen: Consultancy, Honoraria, Other: Speaking Fees, Research Funding; GSK: Consultancy, Research Funding; Abbvie: Consultancy; Array Biopharma: Research Funding; Celgene: Other; Amgen: Consultancy, Honoraria, Other: Speaking Fees, Research Funding; Sanofi: Consultancy, Honoraria, Research Funding; BMS, Celgene: Consultancy, Honoraria, Other: Speaking Fees, Research Funding. Yeh:Janssen: Current Employment. Allred:Janssen: Current Employment. Olyslager:Janssen: Current Employment. Banerjee:Janssen: Current Employment. Goldberg:Johnson & Johnson: Current Employment, Current equity holder in publicly-traded company. Schecter:Janssen: Current Employment. Jackson:Janssen: Current Employment; Memorial Sloan Kettering Cancer Center: Consultancy. Deraedt:Janssen: Current Employment, Current equity holder in publicly-traded company. Gries:Janssen: Current Employment, Current equity holder in publicly-traded company. Fastenau:Janssen: Current Employment, Current equity holder in publicly-traded company. Wu:Legend Biotech USA Inc.: Current Employment. Carrasco:Legend Biotech USA Inc.: Current Employment. Akram:Legend Biotech USA Inc.: Current Employment. Hossain:Legend Biotech USA Inc.: Current Employment. Jakubowiak:AbbVie, Amgen, BMS/Celgene, GSK, Janssen, Karyopharm: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive, Juno: Consultancy, Honoraria. Jagannath:BMS, Janssen, Karyopharm, Legend Biotech, Sanofi, Takeda: Consultancy.
- Published
- 2020
- Full Text
- View/download PDF
32. A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Author
-
Chari, Ajai, Berdeja, Jesus G., Oriol, Albert, van de Donk, Niels W. C. J., Rodriguez, Paula, Askari, Elham, Mateos, Maria-Victoria, Minnema, Monique C., Verona, Raluca, Girgis, Suzette, Prior, Thomas, Hilder, Brandi W., Russell, Jeffery, Goldberg, Jenna D., and Krishnan, Amrita
- Abstract
Chari: Novartis: Honoraria; Array BioPharma: Honoraria; The Binding Site: Honoraria; Bristol Myers Squibb: Consultancy; Adaptive Biotechnology: Honoraria; Pharmacyclics: Research Funding; Karyopharm: Consultancy; Sanofi Genzyme: Consultancy; Seattle Genetics: Consultancy, Research Funding; Oncopeptides: Consultancy; Takeda: Consultancy, Research Funding; Antengene: Consultancy; Glaxo Smith Kline: Consultancy; Secura Bio: Consultancy; Amgen: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Janssen: Consultancy, Research Funding. Berdeja:Takeda: Consultancy, Research Funding; Servier: Consultancy; Teva: Research Funding; Prothena: Consultancy; Poseida: Research Funding; Lilly: Research Funding; Novartis: Research Funding; Acetylon: Research Funding; BMS: Consultancy, Research Funding; CURIS: Research Funding; Karyopharm: Consultancy; Bluebird: Research Funding; EMD Sorono: Research Funding; Bioclinica: Consultancy; Kesios: Research Funding; Amgen: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Genentech, Inc.: Research Funding; Kite Pharma: Consultancy; CRISPR Therapeutics: Consultancy, Research Funding; Abbvie: Research Funding; Constellation: Research Funding; Cellularity: Research Funding; Vivolux: Research Funding; Legend: Consultancy; Glenmark: Research Funding; Celgene: Consultancy, Research Funding. Oriol:Janssen: Consultancy; Amgen: Consultancy, Speakers Bureau; Sanofi: Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. van de Donk:BMS: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; TAKEDA: Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees; Bayer: Membership on an entity's Board of Directors or advisory committees; ROCHE: Membership on an entity's Board of Directors or advisory committees; AMGEN: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding. Rodriguez:Oncopeptides: Consultancy; Sanofi: Consultancy; Abbvie: Consultancy; Kite: Consultancy; GSK: Consultancy; Janssen: Consultancy, Honoraria; Celgene-BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria; Medscape: Membership on an entity's Board of Directors or advisory committees. Askari:Hospital Universitario Fundacion Jimenez Diaz: Consultancy, Current Employment. Mateos:Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy; Pharmamar: Consultancy; Adaptive: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; EDOMundipharma: Consultancy; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Minnema:Janssen Cilag: Honoraria; Celgene Corporation: Honoraria, Research Funding; Gilead: Honoraria; Amgen: Honoraria; Servier: Honoraria. Verona:Johnson & Johnson: Current Employment, Current equity holder in publicly-traded company. Girgis:Johnson & Johnson: Current Employment, Current equity holder in publicly-traded company. Prior:Johnson & Johnson: Current Employment, Current equity holder in publicly-traded company. Hilder:Johnson & Johnson: Current Employment, Current equity holder in publicly-traded company. Russell:Johnson & Johnson: Current Employment, Current equity holder in publicly-traded company. Goldberg:Johnson & Johnson: Current Employment, Current equity holder in publicly-traded company. Krishnan:Takeda: Speakers Bureau; Sanofi: Consultancy; Sutro: Membership on an entity's Board of Directors or advisory committees; Z Predicta: Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy; Regeneron: Consultancy; Amgen: Speakers Bureau; BMS/Celgene: Consultancy, Other: Stock BMS, Speakers Bureau.
- Published
- 2020
- Full Text
- View/download PDF
33. A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Author
-
Chari, Ajai, Berdeja, Jesus G., Oriol, Albert, van de Donk, Niels W. C.J., Rodriguez, Paula, Askari, Elham, Mateos, Maria-Victoria, Minnema, Monique C., Verona, Raluca, Girgis, Suzette, Prior, Thomas, Hilder, Brandi W., Russell, Jeffery, Goldberg, Jenna D., and Krishnan, Amrita
- Published
- 2020
- Full Text
- View/download PDF
34. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation
- Author
-
Perales, Miguel-Angel, Goldberg, Jenna D., Yuan, Jianda, Koehne, Guenther, Lechner, Lauren, Papadopoulos, Esperanza B., Young, James W., Jakubowski, Ann A., Zaidi, Bushra, Gallardo, Humilidad, Liu, Cailian, Rasalan, Teresa, Wolchok, Jedd D., Croughs, Therese, Morre, Michel, Devlin, Sean M., and van den Brink, Marcel R.M.
- Abstract
Delays in immune recovery after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are associated with increased risks of infection and relapse. IL-7 has a central role in T-cell development and survival and enhances immune recovery in murine models of allo-HSCT. We performed a phase 1 trial of r-hIL-7 (CYT107) in recipients of T-cell depleted allo-HSCTs. Twelve patients were treated with escalating doses of r-hIL-7 administered weekly for 3 weeks. The study drug was well tolerated with only one patient developing acute skin GVHD. At baseline, patients were profoundly lymphopenic. CYT107 induced a doubling in CD4+and CD8+T cells. The main effect of IL-7 was an expansion of effector memory T cells, the predominant subset identified in our patients. There was no significant effect on CD4+CD25+FoxP3+T cells, NK, or B cells. Importantly, we not only saw quantitative increases in T cells after a short course of IL-7 but also demonstrated an increase in functional T cells, including viral-specific T cells that recognize CMV. Enhanced TCR diversity was also observed after treatment. Our results indicate that r-hIL-7 can enhance immune recovery after a T cell–depleted allo-HSCT without causing significant GVHD or other serious toxicity (www.clinicaltrials.gov; NCT00684008).
- Published
- 2012
- Full Text
- View/download PDF
35. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation
- Author
-
Perales, Miguel-Angel, Goldberg, Jenna D., Yuan, Jianda, Koehne, Guenther, Lechner, Lauren, Papadopoulos, Esperanza B., Young, James W., Jakubowski, Ann A., Zaidi, Bushra, Gallardo, Humilidad, Liu, Cailian, Rasalan, Teresa, Wolchok, Jedd D., Croughs, Therese, Morre, Michel, Devlin, Sean M., and van den Brink, Marcel R. M.
- Abstract
Delays in immune recovery after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are associated with increased risks of infection and relapse. IL-7 has a central role in T-cell development and survival and enhances immune recovery in murine models of allo-HSCT. We performed a phase 1 trial of r-hIL-7 (CYT107) in recipients of T-cell depleted allo-HSCTs. Twelve patients were treated with escalating doses of r-hIL-7 administered weekly for 3 weeks. The study drug was well tolerated with only one patient developing acute skin GVHD. At baseline, patients were profoundly lymphopenic. CYT107 induced a doubling in CD4+ and CD8+ T cells. The main effect of IL-7 was an expansion of effector memory T cells, the predominant subset identified in our patients. There was no significant effect on CD4+CD25+FoxP3+ T cells, NK, or B cells. Importantly, we not only saw quantitative increases in T cells after a short course of IL-7 but also demonstrated an increase in functional T cells, including viral-specific T cells that recognize CMV. Enhanced TCR diversity was also observed after treatment. Our results indicate that r-hIL-7 can enhance immune recovery after a T cell–depleted allo-HSCT without causing significant GVHD or other serious toxicity (www.clinicaltrials.gov; NCT00684008).
- Published
- 2012
- Full Text
- View/download PDF
36. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation
- Author
-
Jenq, Robert R., Ubeda, Carles, Taur, Ying, Menezes, Clarissa C., Khanin, Raya, Dudakov, Jarrod A., Liu, Chen, West, Mallory L., Singer, Natalie V., Equinda, Michele J., Gobourne, Asia, Lipuma, Lauren, Young, Lauren F., Smith, Odette M., Ghosh, Arnab, Hanash, Alan M., Goldberg, Jenna D., Aoyama, Kazutoshi, Blazar, Bruce R., Pamer, Eric G., and R.M. van den Brink, Marcel
- Abstract
Despite a growing understanding of the link between intestinal inflammation and resident gut microbes, longitudinal studies of human flora before initial onset of intestinal inflammation have not been reported. Here, we demonstrate in murine and human recipients of allogeneic bone marrow transplantation (BMT) that intestinal inflammation secondary to graft-versus-host disease (GVHD) is associated with major shifts in the composition of the intestinal microbiota. The microbiota, in turn, can modulate the severity of intestinal inflammation. In mouse models of GVHD, we observed loss of overall diversity and expansion of Lactobacillales and loss of Clostridiales. Eliminating Lactobacillales from the flora of mice before BMT aggravated GVHD, whereas reintroducing the predominant species of Lactobacillus mediated significant protection against GVHD. We then characterized gut flora of patients during onset of intestinal inflammation caused by GVHD and found patterns mirroring those in mice. We also identified increased microbial chaos early after allogeneic BMT as a potential risk factor for subsequent GVHD. Together, these data demonstrate regulation of flora by intestinal inflammation and suggest that flora manipulation may reduce intestinal inflammation and improve outcomes for allogeneic BMT recipients.
- Published
- 2012
- Full Text
- View/download PDF
37. Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study
- Author
-
Rodriguez-Otero, Paula, Dholaria, Bhagirathbhai, Askari, Elham, Reece, Donna E., van de Donk, Niels W.C.J., Chari, Ajai, Goldschmidt, Hartmut, Krishnan, Amrita Y., Martin, Thomas, Mateos, Maria-Victoria, Morillo Giles, Daniel, Rodriguez, Cesar, Rosinol, Laura, San-Miguel, Jesús F., Sureda, Anna, Wäsch, Ralph, Weisel, Katja, Verona, Raluca I., Wang Lin, Shun Xin, Prior, Thomas J., Weiss, Brendan M., Wade, Mark, Goldberg, Jenna D., Oriol, Albert, and Hari, Parameswaran
- Abstract
Introduction:Teclistamab (Tec) is a B-cell maturation antigen × CD3 T-cell redirecting bispecific antibody. In the phase 1 MajesTEC-1 trial in patients (pts) with heavily pretreated relapsed/refractory multiple myeloma (RRMM), Tec monotherapy was well tolerated and yielded an overall response rate of 65% and very good partial response or better rate of 58% at the recommended phase 2 dose (RP2D) with 6.1 months' median follow-up; responses were durable and deepened over time. Daratumumab (Dara) is a monoclonal antibody that targets CD38 and is approved for the treatment of MM. In addition to direct cytotoxicity, Dara has immunomodulatory effects, including promotion of T-cell expansion and depletion of suppressive CD38+ immunoregulatory cells, making it a rational partner for T-cell redirection. In preclinical studies, the lytic activity of Tec against MM cell lines was enhanced by pretreatment and combination treatment with Dara. By targeting discrete yet complementary antigens, combination of Tec and Dara may improve efficacy in pts with RRMM. We present data for pts with RRMM who received Tec + Dara in a phase 1b multicohort study (TRIMM-2; NCT04108195).
- Published
- 2021
- Full Text
- View/download PDF
38. Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
- Author
-
Moreau, Philippe, Usmani, Saad Z., Garfall, Alfred L., van de Donk, Niels W.C.J., Nahi, Hareth, San-Miguel, Jesus, Oriol, Albert, Nooka, Ajay K., Martin, Thomas, Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Benboubker, Lotfi, Mateos, Maria-Victoria, Bahlis, Nizar J., Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Sidana, Surbhi, Pei, Lixia, Trancucci, Danielle, Verona, Raluca I., Girgis, Suzette, Olyslager, Yunsi, Jaffe, Mindy, Uhlar, Clarissa M., Stephenson, Tara, Van Rampelbergh, Rian, Banerjee, Arnob, Goldberg, Jenna D., Kobos, Rachel, and Krishnan, Amrita Y.
- Abstract
Introduction:Teclistamab (JNJ-64007957) is a T-cell redirecting, bispecific IgG4 antibody that targets both B-cell maturation antigen (BCMA) and CD3 receptors to induce T-cell mediated cytotoxicity of BCMA-expressing myeloma cells. Teclistamab is under investigation in MajesTEC-1, an ongoing phase 1/2 study in patients (pts) with heavily pretreated relapsed/refractory multiple myeloma (RRMM). Results from the phase 1 study (parts 1 and 2; NCT03145181) indicated that teclistamab is well tolerated at the recommended phase 2 dose (RP2D) and has encouraging efficacy, with an overall response rate (ORR) of 65% and very good partial response or better (≥VGPR) rate of 58% in 40 pts after a median of 6.1 mo of follow-up. Here we report for the first time initial data from the phase 2 portion of MajesTEC-1 (part 3; NCT04557098) and updated results for phase 1 pts treated at the RP2D.
- Published
- 2021
- Full Text
- View/download PDF
39. Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma
- Author
-
Chari, Ajai, Hari, Parameswaran, Bahlis, Nizar J., Mateos, Maria-Victoria, van de Donk, Niels W.C.J., Dholaria, Bhagirathbhai, Garfall, Alfred L., Goldschmidt, Hartmut, Kortuem, K. Martin, Krishnan, Amrita Y., Martin, Thomas, Morillo Giles, Daniel, Oriol, Albert, Reece, Donna E., Rodriguez, Cesar, Rodriguez-Otero, Paula, San-Miguel, Jesús F., Usmani, Saad Z., Verona, Raluca I., Wang Lin, Shun Xin, Prior, Thomas J., Wade, Mark, Weiss, Brendan M., Goldberg, Jenna D., and Askari, Elham
- Abstract
Introduction:Novel agents are needed for multiple myeloma (MM), which remains incurable with most patients (pts) relapsing or becoming refractory to standard therapies. Talquetamab (Tal) is a bispecific antibody that binds to G protein-coupled receptor family C group 5 member D (GPRC5D), a receptor highly expressed on plasma cells with limited expression in healthy tissue, and CD3 to redirect T cells to GPRC5D-expressing MM cells. Tal monotherapy at the recommended phase 2 dose (RP2D) was well tolerated and yielded an overall response rate of 70% after 6.3 months of follow-up in pts with relapsed/refractory MM (RRMM) in the phase 1 MonumenTAL-1 study; responses were durable and continued to deepen over time. Daratumumab (Dara) is a monoclonal antibody approved for MM treatment that targets CD38 on MM cells, resulting in direct cytotoxicity of MM cells. Dara also impacts immune cell populations, ie, increasing helper and cytotoxic T cells and decreasing suppressive CD38+ immunoregulatory cells. Preclinical studies showed addition of Dara enhanced Tal-mediated lysis of MM cells, suggesting the combination may also increase clinical activity in pts with RRMM. We report initial findings for pts with RRMM who received Tal + Dara in a phase 1b multicohort study (TRIMM-2; NCT04108195).
- Published
- 2021
- Full Text
- View/download PDF
40. Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
- Author
-
Krishnan, Amrita Y., Minnema, Monique C., Berdeja, Jesús G., Oriol, Albert, van de Donk, Niels W.C.J., Rodriguez-Otero, Paula, Askari, Elham, Mateos, Maria-Victoria, Costa, Luciano J., Verona, Raluca I., Ma, Xuewen, Girgis, Suzette, Yang, Shiyi, Hilder, Brandi W., Russell, Jeffery, Goldberg, Jenna D., and Chari, Ajai
- Abstract
Introduction:Despite recent advances in treatment, patients with multiple myeloma (MM) continue to relapse. G protein-coupled receptor family C group 5 member D (GPRC5D) is a promising target for immunotherapy in patients with MM due to its high expression in malignant plasma cells and limited expression in normal human tissue; unlike other antigens targeted by MM therapies, there is no indication that GPRC5D sheds into the periphery. Talquetamab (JNJ-64407564) is a first-in-class bispecific IgG4 antibody that redirects T cells to kill MM cells by binding to both GPRC5D and CD3 receptors. Here we report updated and new results of talquetamab at the recommended phase 2 doses (RP2Ds) from a phase 1 trial in relapsed/refractory MM (RRMM; NCT03399799).
- Published
- 2021
- Full Text
- View/download PDF
41. Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma
- Author
-
Martin, Thomas, Usmani, Saad Z., Berdeja, Jesús G., Jakubowiak, Andrzej, Agha, Mounzer, Cohen, Adam D, Hari, Parameswaran, Avigan, David, Deol, Abhinav, Htut, Myo, Lesokhin, Alexander, Munshi, Nikhil C., O'Donnell, Elizabeth, Stewart, A. Keith, Schecter, Jordan M., Goldberg, Jenna D., Jackson, Carolyn C., Yeh, Tzu-Min, Banerjee, Arnob, Allred, Alicia, Zudaire, Enrique, Deraedt, William, Madduri, Deepu, Olyslager, Yunsi, Zhou, Changwei, Pacaud, Lida, Lin, Yi, and Jagannath, Sundar
- Published
- 2021
- Full Text
- View/download PDF
42. Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
- Author
-
Moreau, Philippe, Usmani, Saad Z., Garfall, Alfred L., van de Donk, Niels W.C.J., Nahi, Hareth, San-Miguel, Jesus, Oriol, Albert, Nooka, Ajay K., Martin, Thomas, Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Benboubker, Lotfi, Mateos, Maria-Victoria, Bahlis, Nizar J., Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Sidana, Surbhi, Pei, Lixia, Trancucci, Danielle, Verona, Raluca I., Girgis, Suzette, Olyslager, Yunsi, Jaffe, Mindy, Uhlar, Clarissa M., Stephenson, Tara, Van Rampelbergh, Rian, Banerjee, Arnob, Goldberg, Jenna D., Kobos, Rachel, and Krishnan, Amrita Y.
- Abstract
Moreau: Celgene BMS: Honoraria; Sanofi: Honoraria; Janssen: Honoraria; Abbvie: Honoraria; Amgen: Honoraria; Oncopeptides: Honoraria. Usmani: Janssen Oncology: Consultancy, Research Funding; Takeda: Consultancy, Research Funding, Speakers Bureau; SkylineDX: Consultancy, Research Funding; Seattle Genetics: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; Merck: Consultancy, Research Funding; Sanofi: Consultancy, Research Funding, Speakers Bureau; Janssen: Consultancy, Research Funding, Speakers Bureau; EdoPharma: Consultancy; GSK: Consultancy, Research Funding; Celgene/BMS: Consultancy, Research Funding, Speakers Bureau; Array BioPharma: Consultancy, Research Funding; Abbvie: Consultancy; Amgen: Consultancy, Research Funding, Speakers Bureau; Bristol-Myers Squibb: Research Funding. Garfall: Amgen: Honoraria; Tmunity Therapeutics: Research Funding; Novartis: Research Funding; GSK: Honoraria; Janssen: Honoraria, Research Funding. van de Donk: BMS/Celgene: Consultancy, Honoraria; Janssen: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; Cellectis: Research Funding; Takeda: Consultancy; Roche: Consultancy; Novartis /bayer/servier: Consultancy. Nahi: XNK Therapeutics AB: Consultancy. San-Miguel: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Merck Sharpe & Dohme, Novartis, Regeneron, Roche, Sanofi, SecuraBio, and Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees. Oriol: GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Nooka: GlaxoSmithKline: Consultancy, Other: Travel expenses; Bristol-Myers Squibb: Consultancy; Sanofi: Consultancy; Oncopeptides: Consultancy; Janssen Oncology: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; Adaptive technologies: Consultancy; Karyopharm Therapeutics: Consultancy. Martin: Amgen: Research Funding; Sanofi: Research Funding; Janssen: Research Funding; GlaxoSmithKline: Consultancy; Oncopeptides: Consultancy. Rosinol: Janssen, Celgene, Amgen and Takeda: Honoraria. Chari: Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS/Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Shattuck Labs: Consultancy, Membership on an entity's Board of Directors or advisory committees; Millenium/Takeda: Consultancy, Research Funding; Secura Bio: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi Genzyme: Consultancy, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Consultancy, Membership on an entity's Board of Directors or advisory committees; Antengene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Research Funding; Novartis: Consultancy, Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Research Funding; Janssen Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Karlin: Abbvie: Honoraria; Amgen: Honoraria, Other: travel support and advisory board ; GSK: Honoraria, Other: member of advisory board; Janssen: Honoraria, Other: member of advisory board, travel support; Takeda: Honoraria, Other: member of advisory board; Celgene-BMS: Honoraria, Other: member of advisory board; Sanofi: Honoraria; oncopeptide: Honoraria. Mateos: Regeneron: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene - Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bluebird bio: Honoraria; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sea-Gen: Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Honoraria; Oncopeptides: Honoraria. Bahlis: Janssen: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Genentech: Consultancy; Sanofi: Consultancy, Honoraria; GlaxoSmithKline: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria. Popat: Takeda: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; AbbVie, BMS, Janssen, Oncopeptides, and Amgen: Honoraria; GlaxoSmithKline: Consultancy, Honoraria, Research Funding; Abbvie, Takeda, Janssen, and Celgene: Consultancy; Janssen and BMS: Other: travel expenses. Besemer: GSK: Honoraria; Janssen: Honoraria; Takeda: Honoraria. Martínez-López: Janssen, BMS, Novartis, Incyte, Roche, GSK, Pfizer: Consultancy; Roche, Novartis, Incyte, Astellas, BMS: Research Funding. Sidana: Allogene: Research Funding; Janssen: Consultancy, Research Funding; Magenta Therapeutics: Consultancy, Research Funding; BMS: Consultancy. Pei: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Trancucci: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Verona: Janssen: Current Employment. Girgis: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Olyslager: Janssen: Current Employment. Jaffe: Janssen: Current Employment. Uhlar: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Stephenson: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Van Rampelbergh: Janssen: Current Employment. Banerjee: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Goldberg: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Kobos: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Krishnan: MAGENTA: Consultancy; BMS: Consultancy, Current equity holder in publicly-traded company, Speakers Bureau; JANSSEN: Consultancy, Research Funding; City of Hope Cancer Center: Current Employment; REGENERON: Consultancy; SANOFI: Consultancy; GSK: Consultancy; Amgen: Speakers Bureau.
- Published
- 2021
- Full Text
- View/download PDF
43. Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
- Author
-
Krishnan, Amrita Y., Minnema, Monique C., Berdeja, Jesús G., Oriol, Albert, van de Donk, Niels W.C.J., Rodriguez-Otero, Paula, Askari, Elham, Mateos, Maria-Victoria, Costa, Luciano J., Verona, Raluca I., Ma, Xuewen, Girgis, Suzette, Yang, Shiyi, Hilder, Brandi W., Russell, Jeffery, Goldberg, Jenna D., and Chari, Ajai
- Abstract
Krishnan: MAGENTA: Consultancy; BMS: Consultancy, Current equity holder in publicly-traded company, Speakers Bureau; JANSSEN: Consultancy, Research Funding; City of Hope Cancer Center: Current Employment; REGENERON: Consultancy; SANOFI: Consultancy; GSK: Consultancy; Amgen: Speakers Bureau. Minnema: Celgene: Other: Travel expenses; Alnylam: Consultancy; Cilag: Consultancy; BMS: Consultancy; Janssen: Consultancy; Kite/Gilead: Consultancy. Berdeja: Lilly, Novartis: Research Funding; Abbvie, Acetylon, Amgen: Research Funding; Celularity, CRISPR Therapeutics: Research Funding; EMD Sorono, Genentech: Research Funding; Poseida, Sanofi, Teva: Research Funding; Bluebird bio, BMS, Celgene, CRISPR Therapeutics, Janssen, Kite Pharma, Legend Biotech, SecuraBio, Takeda: Consultancy; GSK, Ichnos Sciences, Incyte: Research Funding. Oriol: Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. van de Donk: Roche: Consultancy; Takeda: Consultancy; Cellectis: Research Funding; Amgen: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; BMS/Celgene: Consultancy, Honoraria; Novartis /bayer/servier: Consultancy. Rodriguez-Otero: Clínica Universidad de Navarra: Current Employment; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene-BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Kite: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria; Regeneron: Honoraria. Askari: Janssen: Research Funding. Mateos: Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sea-Gen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Regeneron: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene - Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Honoraria; Bluebird bio: Honoraria; AbbVie: Honoraria; GSK: Honoraria; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees. Costa: BMS: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Karyopharm: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria, Speakers Bureau. Verona: Janssen: Current Employment. Ma: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Girgis: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Yang: Janssen: Current Employment. Hilder: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Russell: Janssen: Ended employment in the past 24 months. Goldberg: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Chari: Shattuck Labs: Consultancy, Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Millenium/Takeda: Consultancy, Research Funding; Sanofi Genzyme: Consultancy, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Antengene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Research Funding; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics: Research Funding; Secura Bio: Consultancy, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Research Funding; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding.
- Published
- 2021
- Full Text
- View/download PDF
44. Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study
- Author
-
Rodriguez-Otero, Paula, Dholaria, Bhagirathbhai, Askari, Elham, Reece, Donna E., van de Donk, Niels W.C.J., Chari, Ajai, Goldschmidt, Hartmut, Krishnan, Amrita Y., Martin, Thomas, Mateos, Maria-Victoria, Morillo Giles, Daniel, Rodriguez, Cesar, Rosinol, Laura, San-Miguel, Jesús F., Sureda, Anna, Wäsch, Ralph, Weisel, Katja, Verona, Raluca I., Wang Lin, Shun Xin, Prior, Thomas J., Weiss, Brendan M., Wade, Mark, Goldberg, Jenna D., Oriol, Albert, and Hari, Parameswaran
- Abstract
Rodriguez-Otero: Amgen: Honoraria; Kite: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene-BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Clínica Universidad de Navarra: Current Employment; Regeneron: Honoraria. Dholaria: Takeda: Research Funding; Janssen: Research Funding; Pfizer: Research Funding; Jazz: Speakers Bureau; MEI: Research Funding; Angiocrine: Research Funding; Poseida: Research Funding; Celgene: Speakers Bureau. Askari: Janssen: Research Funding. Reece: Karyopharm: Consultancy, Research Funding; GSK: Honoraria; Millennium: Research Funding; Amgen: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Research Funding; BMS: Honoraria, Research Funding; Sanofi: Honoraria; Takeda: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding. van de Donk: Cellectis: Research Funding; Roche: Membership on an entity's Board of Directors or advisory committees; Bayer: Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Membership on an entity's Board of Directors or advisory committees; Janssen Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding. Chari: Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Consultancy, Membership on an entity's Board of Directors or advisory committees; Secura Bio: Consultancy, Membership on an entity's Board of Directors or advisory committees; Shattuck Labs: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Millenium/Takeda: Consultancy, Research Funding; Sanofi Genzyme: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics: Research Funding; Antengene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Goldschmidt: MSD: Research Funding; Mundipharma: Research Funding; Novartis: Honoraria, Research Funding; Dietmar-Hopp-Foundation: Other: Grant; Sanofi: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Takeda: Consultancy, Research Funding; Molecular Partners: Research Funding; Johns Hopkins University: Other: Grant; Janssen: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Incyte: Research Funding; GSK: Honoraria; Chugai: Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; BMS: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Celgene: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Adaptive Biotechnology: Consultancy; Amgen: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding. Krishnan: City of Hope Cancer Center: Current Employment; JANSSEN: Consultancy, Research Funding; BMS: Consultancy, Current equity holder in publicly-traded company, Speakers Bureau; MAGENTA: Consultancy; REGENERON: Consultancy; SANOFI: Consultancy; GSK: Consultancy; Amgen: Speakers Bureau. Martin: Sanofi: Research Funding; Oncopeptides: Consultancy; Janssen: Research Funding; Amgen: Research Funding; GlaxoSmithKline: Consultancy. Mateos: Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Regeneron: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene - Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sea-Gen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria; Bluebird bio: Honoraria; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Honoraria; Oncopeptides: Honoraria. Morillo Giles: Janssen: Honoraria; Takeda: Honoraria; Abbvie: Honoraria. Rodriguez: Takeda: Consultancy, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; BMS: Consultancy, Speakers Bureau; Amgen: Consultancy, Speakers Bureau; Oncopeptides: Consultancy, Honoraria; Karyopharm: Consultancy, Speakers Bureau. Rosinol: Janssen, Celgene, Amgen and Takeda: Honoraria. San-Miguel: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Merck Sharpe & Dohme, Novartis, Regeneron, Roche, Sanofi, SecuraBio, Takeda: Consultancy, Other: Advisory board. Sureda: Bluebird: Membership on an entity's Board of Directors or advisory committees; MSD: Consultancy, Honoraria, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kite, a Gilead Company: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; GSK: Consultancy, Honoraria, Speakers Bureau; Roche: Other: Support for attending meetings and/or travel; Mundipharma: Consultancy; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel, Research Funding, Speakers Bureau. Wäsch: Amgen: Consultancy, Honoraria; Pfizer: Consultancy; Sanofi: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Novartis: Consultancy; BMS/Celgene: Consultancy; Gilead: Consultancy. Weisel: Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Karyopharm: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy; Novartis: Honoraria; Pfizer: Honoraria. Verona: Janssen: Current Employment. Wang Lin: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Prior: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Weiss: Janssen: Current holder of individual stocks in a privately-held company, Ended employment in the past 24 months. Wade: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Goldberg: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Oriol: Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Hari: Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Millenium: Membership on an entity's Board of Directors or advisory committees, Research Funding; Karyopharm: Consultancy; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Celgene-BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Adaptive Biotech: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau.
- Published
- 2021
- Full Text
- View/download PDF
45. Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma
- Author
-
Martin, Thomas, Usmani, Saad Z., Berdeja, Jesús G., Jakubowiak, Andrzej, Agha, Mounzer, Cohen, Adam D, Hari, Parameswaran, Avigan, David, Deol, Abhinav, Htut, Myo, Lesokhin, Alexander, Munshi, Nikhil C., O'Donnell, Elizabeth, Stewart, A. Keith, Schecter, Jordan M., Goldberg, Jenna D., Jackson, Carolyn C., Yeh, Tzu-Min, Banerjee, Arnob, Allred, Alicia, Zudaire, Enrique, Deraedt, William, Madduri, Deepu, Olyslager, Yunsi, Zhou, Changwei, Pacaud, Lida, Lin, Yi, and Jagannath, Sundar
- Abstract
Martin: GlaxoSmithKline: Consultancy; Janssen: Research Funding; Sanofi: Research Funding; Amgen: Research Funding. Usmani: Takeda: Consultancy, Research Funding, Speakers Bureau; SkylineDX: Consultancy, Research Funding; Seattle Genetics: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; Merck: Consultancy, Research Funding; Janssen Oncology: Consultancy, Research Funding; Bristol-Myers Squibb: Research Funding; EdoPharma: Consultancy; Array BioPharma: Consultancy, Research Funding; Celgene/BMS: Consultancy, Research Funding, Speakers Bureau; GSK: Consultancy, Research Funding; Sanofi: Consultancy, Research Funding, Speakers Bureau; Janssen: Consultancy, Research Funding, Speakers Bureau; Amgen: Consultancy, Research Funding, Speakers Bureau; Abbvie: Consultancy. Berdeja: Lilly, Novartis: Research Funding; Poseida, Sanofi, Teva: Research Funding; GSK, Ichnos Sciences, Incyte: Research Funding; Bluebird bio, BMS, Celgene, CRISPR Therapeutics, Janssen, Kite Pharma, Legend Biotech, SecuraBio, Takeda: Consultancy; Celularity, CRISPR Therapeutics: Research Funding; Abbvie, Acetylon, Amgen: Research Funding; EMD Sorono, Genentech: Research Funding. Jakubowiak: Amgen: Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Gracell: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees. Cohen: Novartis: Research Funding; BMS/Celgene: Consultancy; Takeda: Consultancy; Genentech/Roche: Consultancy; Oncopeptides: Consultancy; AstraZeneca: Consultancy; Janssen: Consultancy; GlaxoSmithKline: Consultancy, Research Funding. Hari: Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Karyopharm: Consultancy; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Millenium: Membership on an entity's Board of Directors or advisory committees, Research Funding; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Adaptive Biotech: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Celgene-BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau. Avigan: Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics: Research Funding; Kite Pharma: Consultancy, Research Funding; Juno: Membership on an entity's Board of Directors or advisory committees; Partner Tx: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Aviv MedTech Ltd: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Legend Biotech: Membership on an entity's Board of Directors or advisory committees; Chugai: Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy; Parexcel: Consultancy; Takeda: Consultancy; Sanofi: Consultancy. Deol: Kite, a Gilead Company: Consultancy. Lesokhin: bristol myers squibb: Research Funding; Iteos: Consultancy; pfizer: Consultancy, Research Funding; Behringer Ingelheim: Honoraria; Trillium Therapeutics: Consultancy; Serametrix, Inc: Patents & Royalties; Genetech: Research Funding; Janssen: Honoraria, Research Funding. Munshi: Adaptive Biotechnology: Consultancy; Karyopharm: Consultancy; Oncopep: Consultancy, Current equity holder in publicly-traded company, Other: scientific founder, Patents & Royalties; Legend: Consultancy; Novartis: Consultancy; Abbvie: Consultancy; Celgene: Consultancy; Janssen: Consultancy; Takeda: Consultancy; Amgen: Consultancy; Pfizer: Consultancy; Bristol-Myers Squibb: Consultancy. O'Donnell: Onocopeptide: Consultancy; Karyopharm: Consultancy; Janssen: Consultancy; Bristol Myer Squibb: Consultancy; Adaptive: Consultancy; Takeda: Consultancy. Stewart: Oncopeptides: Honoraria; Janssen: Honoraria; GSK: Honoraria; BMS: Honoraria; Amgen: Honoraria; Skyline diagnostics: Consultancy; Genomcs England: Membership on an entity's Board of Directors or advisory committees; Tempus Inc.: Current holder of individual stocks in a privately-held company, Membership on an entity's Board of Directors or advisory committees; PikSci Inc.: Current holder of individual stocks in a privately-held company, Patents & Royalties; Sanofi Aventis: Honoraria. Schecter: Janssen: Current Employment, Current holder of stock options in a privately-held company. Goldberg: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Jackson: Janssen: Current Employment; Memorial Sloan Kettering Cancer Center: Consultancy. Yeh: Janssen: Current Employment. Banerjee: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Allred: Janssen: Current Employment, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Zudaire: Janssen: Current Employment. Deraedt: Janssen: Current Employment. Olyslager: Janssen: Current Employment. Pacaud: Legend Biotech: Current Employment. Lin: Juno: Consultancy; Bluebird Bio: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Novartis: Consultancy; Takeda: Research Funding; Kite, a Gilead Company: Consultancy, Research Funding; Vineti: Consultancy; Gamida Cell: Consultancy; Sorrento: Consultancy; Legend: Consultancy; Merck: Research Funding; Janssen: Consultancy, Research Funding. Jagannath: Legend Biotech: Consultancy; Karyopharm Therapeutics: Consultancy; Janssen Pharmaceuticals: Consultancy; Bristol Myers Squibb: Consultancy; Sanofi: Consultancy; Takeda: Consultancy.At the time of abstract submission, cilta-cel is being investigated for the treatment of multiple myeloma but is not yet approved.
- Published
- 2021
- Full Text
- View/download PDF
46. Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma
- Author
-
Chari, Ajai, Hari, Parameswaran, Bahlis, Nizar J., Mateos, Maria-Victoria, van de Donk, Niels W.C.J., Dholaria, Bhagirathbhai, Garfall, Alfred L., Goldschmidt, Hartmut, Kortuem, K. Martin, Krishnan, Amrita Y., Martin, Thomas, Morillo Giles, Daniel, Oriol, Albert, Reece, Donna E., Rodriguez, Cesar, Rodriguez-Otero, Paula, San-Miguel, Jesús F., Usmani, Saad Z., Verona, Raluca I., Wang Lin, Shun Xin, Prior, Thomas J., Wade, Mark, Weiss, Brendan M., Goldberg, Jenna D., and Askari, Elham
- Abstract
Chari: BMS/Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Secura Bio: Consultancy, Membership on an entity's Board of Directors or advisory committees; Shattuck Labs: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Research Funding; Antengene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Millenium/Takeda: Consultancy, Research Funding; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi Genzyme: Consultancy, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Consultancy, Research Funding; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees. Hari: Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Karyopharm: Consultancy; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Adaptive Biotech: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Millenium: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene-BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau. Bahlis: Janssen: Consultancy, Honoraria; Genentech: Consultancy; BMS/Celgene: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; GlaxoSmithKline: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Amgen: Consultancy, Honoraria. Mateos: Sea-Gen: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees; Regeneron: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene - Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bluebird bio: Honoraria; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Honoraria; Oncopeptides: Honoraria. van de Donk: Janssen Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Adaptive Biotechnologies: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Bayer: Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees; Cellectis: Research Funding. Dholaria: Janssen: Research Funding; Takeda: Research Funding; Jazz: Speakers Bureau; MEI: Research Funding; Angiocrine: Research Funding; Poseida: Research Funding; Celgene: Speakers Bureau; Pfizer: Research Funding. Garfall: Janssen: Honoraria, Research Funding; GSK: Honoraria; Novartis: Research Funding; Tmunity Therapeutics: Research Funding; Amgen: Honoraria. Goldschmidt: Novartis: Honoraria, Research Funding; Dietmar-Hopp-Foundation: Other: Grant; Sanofi: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Takeda: Consultancy, Research Funding; MSD: Research Funding; Mundipharma: Research Funding; Molecular Partners: Research Funding; Johns Hopkins University: Other: Grant; Janssen: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Incyte: Research Funding; GSK: Honoraria; Chugai: Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; BMS: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Celgene: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding; Adaptive Biotechnology: Consultancy; Amgen: Consultancy, Honoraria, Other: Grants and/or Provision of Investigational Medicinal Product, Research Funding. Krishnan: City of Hope Cancer Center: Current Employment; JANSSEN: Consultancy, Research Funding; BMS: Consultancy, Current equity holder in publicly-traded company, Speakers Bureau; MAGENTA: Consultancy; REGENERON: Consultancy; SANOFI: Consultancy; GSK: Consultancy; Amgen: Speakers Bureau. Martin: Janssen: Research Funding; Amgen: Research Funding; Oncopeptides: Consultancy; Sanofi: Research Funding; GlaxoSmithKline: Consultancy. Morillo Giles: Janssen: Honoraria; Takeda: Honoraria; Abbvie: Honoraria. Oriol: Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Reece: BMS: Honoraria, Research Funding; GSK: Honoraria; Janssen: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria; Millennium: Research Funding; Karyopharm: Consultancy, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Sanofi: Honoraria. Rodriguez: Takeda: Consultancy, Speakers Bureau; Karyopharm: Consultancy, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Amgen: Consultancy, Speakers Bureau; Oncopeptides: Consultancy, Honoraria; BMS: Consultancy, Speakers Bureau. Rodriguez-Otero: Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene-BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Kite: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria; Regeneron: Honoraria; Clínica Universidad de Navarra: Current Employment. San-Miguel: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Merck Sharpe & Dohme, Novartis, Regeneron, Roche, Sanofi, SecuraBio, Takeda: Consultancy, Other: Advisory board. Usmani: Array BioPharma: Consultancy, Research Funding; GSK: Consultancy, Research Funding; Celgene/BMS: Consultancy, Research Funding, Speakers Bureau; Abbvie: Consultancy; Amgen: Consultancy, Research Funding, Speakers Bureau; Janssen: Consultancy, Research Funding, Speakers Bureau; EdoPharma: Consultancy; Merck: Consultancy, Research Funding; Sanofi: Consultancy, Research Funding, Speakers Bureau; Pharmacyclics: Consultancy, Research Funding; Seattle Genetics: Consultancy, Research Funding; SkylineDX: Consultancy, Research Funding; Janssen Oncology: Consultancy, Research Funding; Takeda: Consultancy, Research Funding, Speakers Bureau; Bristol-Myers Squibb: Research Funding. Verona: Janssen: Current Employment. Wang Lin: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Prior: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Wade: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Weiss: Janssen: Current holder of individual stocks in a privately-held company, Ended employment in the past 24 months. Goldberg: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Askari: Janssen: Research Funding.
- Published
- 2021
- Full Text
- View/download PDF
47. Pentostatin for the Treatment of Chronic Graft-Versus-Host Disease in Children
- Author
-
Goldberg, Jenna D., Jacobsohn, David A., Margolis, Jeffrey, Chen, Allen R., Anders, Viki, Phelps, Michele, and Vogelsang, Georgia B.
- Abstract
Chronic graft-versus-host disease (cGVHD) is a major barrier to successful allogeneic stem cell transplantation. Pentostatin has been used to treat cGVHD in a small series of pediatric patients. The authors report the results of the first five pediatric patients receiving pentostatin for refractory cGVHD at Johns Hopkins Hospital. In this early experience, the authors saw considerable symptom response in their patients. Every patient in this series demonstrated a significant improvement in skin and oral symptoms. An increased incidence of infection secondary to pentostatin was not observed. No patient was permanently discontinued from pentostatin subsequent to side effects. If these promising results continue, a trial of pentostatin as a first-line therapy for cGVHD should be considered to potentially reduce our dependence on high-dose steroids for its treatment.
- Published
- 2003
48. Translational Approach of Using Ex Vivo Cytotoxicity and Early Clinical Data to Predict Teclistamab Efficacious Therapeutic Range in Multiple Myeloma Patients
- Author
-
Girgis, Suzette, Wang Lin, Shun Xin, Pillarisetti, Kodandaram, Banerjee, Arnob, Goldberg, Jenna D., Shetty, Shoba, Stephenson, Tara, Hilder, Brandi W., Hanna, Brett, Smit, Jennifer, Adams III, Homer, Sun, Yu-Nien (Tom), Infante, Jeffrey R., Elsayed, Yusri A, and Sharma, Amarnath
- Abstract
B cell maturation antigen (BCMA; CD269; TNFRSF17) is a surface receptor, expressed on benign and malignant plasma cells. The restricted expression of BCMA on B-cell lineage makes it an ideal target for multiple myeloma (MM) immunotherapy. BCMAxCD3 bispecific antibody (Teclistamab; JNJ-64007957) has been developed to recruit CD3+T-cells to BCMA+MM cells. Teclistamab demonstrated potent cytotoxicity in a murine xenograft model and against ex vivo primary MM cells.
- Published
- 2020
- Full Text
- View/download PDF
49. Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Author
-
Garfall, Alfred L., Usmani, Saad Z., Mateos, María-Victoria, Nahi, Hareth, van de Donk, Niels W.C.J., San-Miguel, Jesus F., Oriol Rocafiguera, Albert, Rosinol, Laura, Chari, Ajai, Bhutani, Manisha, Pei, Lixia, Verona, Raluca, Girgis, Suzette, Stephenson, Tara, Goldberg, Jenna D., Banerjee, Arnob, and Krishnan, Amrita
- Abstract
Garfall: Tmunity: Consultancy, Other: Personal fees, Research Funding; Kite Pharma: Other: Personal fees; Amgen: Research Funding; Novartis: Research Funding; GSK: Consultancy; Janssen: Consultancy, Research Funding; Surface Oncology: Consultancy. Usmani:Merck: Consultancy, Research Funding; Seattle Genetics: Consultancy, Research Funding; Incyte: Research Funding; SkylineDX: Consultancy, Research Funding; GSK: Consultancy, Research Funding; Celgene: Other; Amgen: Consultancy, Honoraria, Other: Speaking Fees, Research Funding; Array Biopharma: Research Funding; Abbvie: Consultancy; BMS, Celgene: Consultancy, Honoraria, Other: Speaking Fees, Research Funding; Sanofi: Consultancy, Honoraria, Research Funding; Pharmacyclics: Research Funding; Janssen: Consultancy, Honoraria, Other: Speaking Fees, Research Funding; Takeda: Consultancy, Honoraria, Other: Speaking Fees, Research Funding. Mateos:Adaptive: Consultancy; Amgen: Consultancy; GlaxoSmithKline: Consultancy; Pharmamar: Consultancy; Janssen: Consultancy; Celgene: Consultancy; EDOMundipharma: Consultancy; AbbVie: Consultancy; Takeda: Consultancy. van de Donk:Bayer: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Ferrer: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding. San-Miguel:Amgen, BMS, Celgene, Janssen, MSD, Novartis, Takeda, Sanofi, Roche, Abbvie, GlaxoSmithKline and Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees. Oriol Rocafiguera:Amgen: Consultancy, Speakers Bureau; GSK: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Chari:Seattle Genetics: Consultancy, Research Funding; Karyopharm: Consultancy; Bristol Myers Squibb: Consultancy; Pharmacyclics: Research Funding; Array BioPharma: Honoraria; The Binding Site: Honoraria; Sanofi Genzyme: Consultancy; Adaptive Biotechnology: Honoraria; Novartis: Honoraria; Takeda: Consultancy, Research Funding; Antengene: Consultancy; Amgen: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Secura Bio: Consultancy; Glaxo Smith Kline: Consultancy; Oncopeptides: Consultancy. Bhutani:Prothena: Other: Clinical Trial Funding to Institute; Janssen: Other: Clinical Trial Funding to Institute; Takeda: Other: Clinical trial funding to institute, Speakers Bureau; Amgen: Speakers Bureau; BMS: Other: Clinical trial funding to institute, Speakers Bureau; Sanofi Genzyme: Consultancy; MedImmune: Other: Clinical Trial Funding to Institute. Pei:J&J: Current Employment, Current equity holder in publicly-traded company. Verona:Johnson & Johnson: Current Employment, Current equity holder in publicly-traded company. Girgis:Johnson & Johnson: Current Employment, Current equity holder in private company. Stephenson:Johnson & Johnson: Current Employment, Current equity holder in private company. Goldberg:Johnson & Johnson: Current Employment, Current equity holder in publicly-traded company. Banerjee:Janssen: Current Employment. Krishnan:BMS/Celgene: Consultancy, Other: Stock BMS, Speakers Bureau; Janssen: Consultancy; Takeda: Speakers Bureau; Z Predicta: Membership on an entity's Board of Directors or advisory committees; Amgen: Speakers Bureau; Sanofi: Consultancy; Sutro: Membership on an entity's Board of Directors or advisory committees; Regeneron: Consultancy.
- Published
- 2020
- Full Text
- View/download PDF
50. Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Author
-
Garfall, Alfred L., Usmani, Saad Z., Mateos, María-Victoria, Nahi, Hareth, van de Donk, Niels W.C.J., San-Miguel, Jesus F., Oriol Rocafiguera, Albert, Rosinol, Laura, Chari, Ajai, Bhutani, Manisha, Pei, Lixia, Verona, Raluca, Girgis, Suzette, Stephenson, Tara, Goldberg, Jenna D., Banerjee, Arnob, and Krishnan, Amrita
- Abstract
Background:MM inevitably relapses and becomes refractory to treatment, representing a patient (pt) population with unmet needs. Teclistamab (JNJ-64007957) is a bispecific BCMA x CD3 antibody that induces T cell-mediated cytotoxicity against BCMA-expressing MM cells. Previously presented results from an ongoing study of teclistamab in RRMM (NCT03145181) included a 67% objective response rate [ORR] for the 270 µg/kg dose administered intravenously (iv) (Usmani et al, ASCO 2020 Oral Presentation #100). Here we present updated results and newly available data for subcutaneous (sc) administration.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.